Acceleron Pharma a biopharmaceutical company, engages in developing and commercializing protein therapeutics for cancer and orphan diseases.Read more
Alnylam is a top competitor of Acceleron. Alnylam is a Public company that was founded in 2002 in Cambridge, Massachusetts. Alnylam operates in the Pharmaceuticals industry. Compared to Acceleron, Alnylam has 1,280 more employees.
Lpath is seen as one of Acceleron's biggest rivals. Lpath was founded in 1997, and is headquartered in San Diego, California. Lpath operates in the Pharmaceuticals industry. Lpath generates $52M less revenue vs. Acceleron.
Acceleron's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 79.2M. Over the last four quarters, Acceleron's revenue has decreased by 37.7%. Specifically, in Q1 2021's revenue was $24.8M; in Q4 2020, it was $25.9M; in Q3 2020, it was $22.6M; in Q2 2020, Acceleron's revenue was $39.8M.
No recent acquisitions found related to Acceleron
No recent investments found related to Acceleron